These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 33765428)

  • 1. Neurodegeneration, Alzheimer's disease biomarkers, and longitudinal verbal learning and memory performance in late middle age.
    Allison SL; Jonaitis EM; Koscik RL; Hermann BP; Mueller KD; Cary RP; Ma Y; Rowley HA; Carlsson CM; Asthana S; Zetterberg H; Blennow K; Bendlin BB; Johnson SC
    Neurobiol Aging; 2021 Jun; 102():151-160. PubMed ID: 33765428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR; Ramakers IHGB; Köhler S; Teunissen CE; Koel-Simmelink M; Nathan PJ; Tsolaki M; Wahlund LO; Waldemar G; Hausner L; Vandenberghe R; Johannsen P; Blackwell A; Vanderstichele H; Verhey F; Visser PJ
    J Alzheimers Dis; 2017; 60(3):1119-1128. PubMed ID: 28984585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume.
    Caldwell JZK; Cummings JL; Banks SJ; Palmqvist S; Hansson O
    Alzheimers Res Ther; 2019 Dec; 11(1):109. PubMed ID: 31878968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment.
    Garrett SL; McDaniel D; Obideen M; Trammell AR; Shaw LM; Goldstein FC; Hajjar I
    JAMA Netw Open; 2019 Dec; 2(12):e1917363. PubMed ID: 31834392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.
    Hohman TJ; Bell SP; Jefferson AL;
    JAMA Neurol; 2015 May; 72(5):520-9. PubMed ID: 25751166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's and neurodegenerative disease biomarkers in blood predict brain atrophy and cognitive decline.
    Dark HE; An Y; Duggan MR; Joynes C; Davatzikos C; Erus G; Lewis A; Moghekar AR; Resnick SM; Walker KA
    Alzheimers Res Ther; 2024 Apr; 16(1):94. PubMed ID: 38689358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
    Hey JA; Yu JY; Abushakra S; Schaefer JF; Power A; Kesslak P; Tolar M
    Drugs; 2024 Jul; 84(7):825-839. PubMed ID: 38902572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations of cigarette smoking with memory decline and neurodegeneration among cognitively normal older individuals.
    Wu P; Li W; Cai X; Yan H; Chen M;
    Neurosci Lett; 2020 Jan; 714():134563. PubMed ID: 31678372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J; Hanseeuw BJ; Hatling FB; Judge KA; Schultz AP; Chhatwal JP; Blacker D; Sperling RA; Johnson KA; Hyman BT; Gómez-Isla T
    J Alzheimers Dis; 2017; 60(4):1451-1459. PubMed ID: 29036824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer's and Lewy Body Diseases.
    Schaeffer MJ; Callahan BL;
    J Alzheimers Dis; 2019; 70(3):877-887. PubMed ID: 31282412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spatially distinct atrophy is linked to β-amyloid and tau in preclinical Alzheimer disease.
    Wang L; Benzinger TL; Hassenstab J; Blazey T; Owen C; Liu J; Fagan AM; Morris JC; Ances BM
    Neurology; 2015 Mar; 84(12):1254-60. PubMed ID: 25716355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer's Disease Cerebrospinal Fluid Biomarkers.
    Åhman HB; Giedraitis V; Cedervall Y; Lennhed B; Berglund L; McKee K; Kilander L; Rosendahl E; Ingelsson M; Åberg AC
    J Alzheimers Dis; 2019; 71(s1):S75-S83. PubMed ID: 31104024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.
    Gomar JJ; Conejero-Goldberg C; Davies P; Goldberg TE;
    J Alzheimers Dis; 2016; 51(4):1085-97. PubMed ID: 26967213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
    Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
    JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults.
    Bilgel M; An Y; Helphrey J; Elkins W; Gomez G; Wong DF; Davatzikos C; Ferrucci L; Resnick SM
    Brain; 2018 Aug; 141(8):2475-2485. PubMed ID: 29901697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarker profiling beyond amyloid and tau: cerebrospinal fluid markers, hippocampal atrophy, and memory change in cognitively unimpaired older adults.
    Idland AV; Sala-Llonch R; Watne LO; Brækhus A; Hansson O; Blennow K; Zetterberg H; Sørensen Ø; Walhovd KB; Wyller TB; Fjell AM
    Neurobiol Aging; 2020 Sep; 93():1-15. PubMed ID: 32438258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LAM Test: A New Cognitive Marker for Early Detection in Preclinical Alzheimer's Disease.
    García-Martínez M; Pozueta-Cantudo A; Lage C; Martínez-Dubarbie F; López-García S; Fernández-Matarrubia M; Corrales-Pardo A; Bravo M; Cavada NC; Anuarbe P; Infante J; López-Higuera JM; Rodríguez-Cobo L; Rodríguez-Rodríguez E; Butler CR; Sánchez-Juan P
    J Alzheimers Dis; 2024; 100(3):1039-1053. PubMed ID: 38943389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.